MX2021003187A - Inhibición de la peptidasa específica de ubiquitina 9x. - Google Patents

Inhibición de la peptidasa específica de ubiquitina 9x.

Info

Publication number
MX2021003187A
MX2021003187A MX2021003187A MX2021003187A MX2021003187A MX 2021003187 A MX2021003187 A MX 2021003187A MX 2021003187 A MX2021003187 A MX 2021003187A MX 2021003187 A MX2021003187 A MX 2021003187A MX 2021003187 A MX2021003187 A MX 2021003187A
Authority
MX
Mexico
Prior art keywords
ubiquitin specific
specific peptidase
usp9x
inhibiting ubiquitin
inhibiting
Prior art date
Application number
MX2021003187A
Other languages
English (en)
Inventor
Katherine J Kayser-Bricker
Anna Ericsson
Adam Charles Talbot
Bruce Follows
Tatiana Shelekhin
Scot Mente
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MX2021003187A publication Critical patent/MX2021003187A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La descripción proporciona compuestos químicos nuevos que son útiles como inhibidores de la peptidasa específica de ubiquitina 9X (USP9X). Los compuestos que inhiben la USP9X son útiles en el tratamiento de enfermedades y trastornos relacionados con la modulación de USP9X, tales como el cáncer.
MX2021003187A 2018-09-19 2019-09-19 Inhibición de la peptidasa específica de ubiquitina 9x. MX2021003187A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862733595P 2018-09-19 2018-09-19
PCT/US2019/051841 WO2020061261A1 (en) 2018-09-19 2019-09-19 Inhibiting ubiquitin specific peptidase 9x

Publications (1)

Publication Number Publication Date
MX2021003187A true MX2021003187A (es) 2021-06-23

Family

ID=69887830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003187A MX2021003187A (es) 2018-09-19 2019-09-19 Inhibición de la peptidasa específica de ubiquitina 9x.

Country Status (12)

Country Link
US (1) US20230065368A1 (es)
EP (1) EP3852790A4 (es)
JP (1) JP2022501362A (es)
KR (1) KR20210061400A (es)
CN (1) CN113164571A (es)
AU (1) AU2019345053A1 (es)
BR (1) BR112021004599A2 (es)
CA (1) CA3113423A1 (es)
IL (1) IL281483A (es)
MX (1) MX2021003187A (es)
SG (1) SG11202102526QA (es)
WO (1) WO2020061261A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3448859T (pt) 2017-03-20 2019-10-25 Forma Therapeutics Inc Composições de pirrolopirrole como ativadores de piruvato quinase (pkr).
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
EP4126876A1 (en) 2020-04-01 2023-02-08 Global Blood Therapeutics, Inc. Pyrrolidine-pyrazoles as pyruvate kinase activators
TW202245758A (zh) 2021-02-08 2022-12-01 美商全球血液治療公司 作為丙酮酸激酶活化劑之吡咯啶-吡唑
CN113416188B (zh) * 2021-05-31 2022-12-13 河南偶联生物科技有限公司 一种[1,2,4]三唑并[1,5-a]吡啶化合物的合成方法
WO2023060134A1 (en) 2021-10-06 2023-04-13 Global Blood Therapeutics, Inc. Lactam pyrrolidine-pyrazoles as pyruvate kinase activators
WO2023116774A1 (zh) * 2021-12-21 2023-06-29 赛诺哈勃药业（成都）有限公司 含二氮杂亚基磺酰结构的化合物及其在医药上的用途
WO2024112764A1 (en) * 2022-11-21 2024-05-30 Novo Nordisk Health Care Ag Synthesis of pyrrolo[3,4-c]pyrroles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
JP5852658B2 (ja) * 2010-09-24 2016-02-03 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
WO2015054555A1 (en) * 2013-10-10 2015-04-16 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
WO2016181408A2 (en) * 2015-05-11 2016-11-17 Cadila Healthcare Limited NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST
CN107922415B (zh) * 2015-09-24 2022-04-15 豪夫迈·罗氏有限公司 新的作为双重atx/ca抑制剂的二环化合物
PT3448859T (pt) * 2017-03-20 2019-10-25 Forma Therapeutics Inc Composições de pirrolopirrole como ativadores de piruvato quinase (pkr).
EP3852792A4 (en) * 2018-09-19 2022-07-06 Forma Therapeutics, Inc. INHIBITION OF UBIQUITIN-SPECIFIC PEPTIDASE 9X
EP3853206B1 (en) * 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
CN113226356A (zh) * 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
WO2020191022A1 (en) * 2019-03-18 2020-09-24 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 9x

Also Published As

Publication number Publication date
KR20210061400A (ko) 2021-05-27
CA3113423A1 (en) 2020-03-26
WO2020061261A1 (en) 2020-03-26
SG11202102526QA (en) 2021-04-29
JP2022501362A (ja) 2022-01-06
EP3852790A4 (en) 2022-08-10
IL281483A (en) 2021-04-29
CN113164571A (zh) 2021-07-23
US20230065368A1 (en) 2023-03-02
AU2019345053A1 (en) 2021-05-06
EP3852790A1 (en) 2021-07-28
BR112021004599A2 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12017502203A1 (en) Tyrosine kinase inhibitors
MX2018007267A (es) Compuestos utiles como inhibidores de cinasa.
EA202091964A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
IS8343A (is) Próteasómtálmar og aðferðir til að nota þá
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
EA201991622A1 (ru) Комплексная терапия для лечения рака
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2022001004A (es) Inhibidores de enzimas.
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
EP4306173A3 (en) Compositions and methods for treating cancers
ZA202000354B (en) Novel braf inhibitors and use thereof for treatment of cutaneous reactions
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
NZ740817A (en) Pcna inhibitors
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
MX2022000811A (es) Inhibidores de enzimas.
ZA202106519B (en) Caspase inhibitors and methods of use thereof